Safe­ty, ef­fi­ca­cy and dos­ing ques­tions linger for Lil­ly's Alzheimer's drug ahead of Mon­day ad­comm

The FDA de­tailed its biggest con­cerns about Eli Lil­ly’s ex­per­i­men­tal Alzheimer’s ther­a­py do­nanemab ahead of a last-minute ad­vi­so­ry com­mit­tee meet­ing to con­vene Mon­day about the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER